AbbVie Stock Slides as Insider Selling Spooks Investors

AbbVie ( (ABBV) ) has fallen by -7.40%. Read on to learn why.

AbbVie shares fell 7.40% over the past week, even as Wall Street analysts largely stuck to a bullish stance on the drugmaker. Berenberg Bank’s Luisa Hector and Wells Fargo’s Mohit Bansal both reiterated Buy ratings with price targets well above the current level, while Citi stayed on the sidelines with a Hold. The market’s hesitation contrasts with AbbVie’s most recent quarter, where revenue rose to $16.62 billion and swung from a small GAAP loss a year earlier to $1.82 billion in net profit.

Behind the stock’s pullback, sentiment has been pressured by signs of insider selling and lingering worries that AbbVie’s best days were tied to its blockbuster Humira. Corporate insider activity has turned negative over the past quarter, with several executives, including senior vice president David Ryan Purdue, cashing in shares. That has fed concerns that management sees limited near‑term upside, even as the company continues to promote a robust growth story driven by its newer drugs and a broader pipeline.

Yet the fundamental narrative remains more positive than AbbVie’s recent price action suggests. The company is investing heavily in its immunology franchise, including a new Phase 1 study on risankizumab dosing aimed at supporting longer‑term, more convenient use and defending share against rivals in inflammatory diseases. At the same time, AbbVie is benefiting from strong momentum in Skyrizi and Rinvoq, growing contributions from neuroscience, oncology and aesthetics, and powerful cash generation that funds a roughly 3% dividend. With shares now cheaper after the 7.40% weekly slide, the gap between cautious short‑term sentiment and upbeat long‑term analyst forecasts may offer an opening for investors willing to look past the Humira hangover.